Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on October 3, 2017, reporting events occurring on September 29, 2017. The Company is an emerging growth company incorporated in Delaware, focused on the commercialization of its lead prescription drug product, Mytesi.
Key Financial Metrics and Transaction Details
The filing details an underwritten public offering of common stock. Key transaction metrics include:
- Offering Price: $0.20 per share.
- Firm Shares Sold: 21,250,000 shares.
- Over-Allotment Option: 3,187,500 shares granted to the underwriter (Maxim Group LLC).
- Underwriting Discount: 7% of gross proceeds (subject to reduction for specific institutional investors).
- Estimated Net Proceeds: Approximately $3.55 million (firm shares only) or $4.15 million (if over-allotment is fully exercised).
- Expenses: Company to reimburse underwriter for travel and legal expenses up to $75,000.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this document focuses on the capital raise event rather than periodic financial performance.
Material Changes and Restrictions
The entry into the Underwriting Agreement imposes a 120-day lock-up period (until January 27, 2018) during which the Company cannot issue additional common stock or equivalents without the underwriter's consent. This restriction also covers variable rate transactions. The offering officially closed on October 3, 2017.
Outlook, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to utilize the net proceeds for the commercialization of Mytesi and for working capital and general corporate purposes.
Risks and Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ due to risks and uncertainties. The Company does not plan to update these statements publicly except as required by law.
Investor Verification Checklist
- Verify the final closing amount and whether the over-allotment option was exercised by reviewing the subsequent Form 8-K or press release dated October 3, 2017.
- Confirm the actual net proceeds received after deducting the 7% underwriting discount and the $75,000 expense cap.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific representations, warranties, and indemnification obligations.
- Monitor the Company's cash burn rate relative to the $3.55 million to $4.15 million raised to assess runway for Mytesi commercialization.